Industry News
Pharmaceutical Industry News
Could a Pill Fix the Brain?
Neurologists are exploring medications that would help the brain recover after a stroke or traumatic injury.
It was déjà vu all over again…
It was déjà vu all over again for TV drug ad spending in August, as the top 10 spenders barely deviated from July’s list and turned in a combined total nearly identical to the preceding
PatientPartner transforms pharma…
PatientPartner transforms pharma brands' patient marketing and engagement efforts with the launch of the “PerfectPatient”, an AI-powered mentor that personalizes every patient’s journey.
During a tense and at times…
During a tense and at times incendiary Senate hearing Thursday, Robert F. Kennedy Jr. blamed the pharmaceutical industry and fell back on vaccine misinformation as he sought to defend the tumult that has consumed the
Health Care Costs for Workers Begin to Climb
A survey shows employers expect a sharp increase in benefit costs for next year, and many will want workers to shoulder more of the burden.
As the annual U.S. Conference on…
As the annual U.S. Conference on HIV/AIDS kicks off in Washington, D.C., this week with a focus on aging with HIV, Gilead Sciences is rolling out a corresponding awareness campaign spotlighting several firsthand stories of
Health and Human Services Seretary…
Health and Human Services Seretary Robert F. Kennedy Jr. has selected seven new experts that he plans to nominate to the Advisory Committee on Immunization Practices, the panel that issues recommendations on vaccine use in
Novartis is tapping into Argo’s…
Novartis is tapping into Argo's siRNA capabilities again in a deal worth up to $5.2 billion. The FDA approved a subcutaneous version of Eisai and Biogen's Leqembi. The Hong Kong Stock Exchange issued sanctions against
Citing a “new evidenced based…
Citing a “new evidenced based philosophy,” the FDA’s Center for Biologics Evaluation and Research is preparing to take a hard line against the common practice of administering certain respiratory virus vaccines at the same time.
The FDA issued a warning letter to…
The FDA issued a warning letter to Amneal Pharmaceuticals criticizing the drugmaker for failing to correct problems that led to a string of recalls of its generic vancomycin and ropivacaine hydrochloride products.
ImmunoPrecise Antibodies has…
ImmunoPrecise Antibodies has cemented a recent shift in its focus by adopting a new name: MindWalk. The new brand, which also covers the company’s BioStrand and Talem subsidiaries, is designed to convey the increased focus
Texas Senate Passes Bill to Crack Down on Mail-Order Abortion Pills
Gov. Greg Abbott is expected to sign the legislation, which allows nearly anyone to sue abortion medication providers and distributors.
F.D.A. Official Overruled Scientists on Wide Access to Covid Shots
The agency’s staff scientists pointed out how Covid was still unpredictable and posed a threat to toddlers, but the official decided to restrict shots only to children with risk factors.
Point of Care revenue surpassed…
Point of Care revenue surpassed $1B in 2024—see why it’s becoming a cornerstone of healthcare media strategies.
A new awareness-raising effort…
A new awareness-raising effort from Incyte is aimed at giving doctors an up-close look at the emotional and physical challenges their patients with hidradenitis suppurativa face.
Ori Biotech has lassoed a…
Ori Biotech has lassoed a significant milestone for its cell and gene therapy manufacturing platform, IRO, which now boasts a coveted Advanced Manufacturing Technology designation from the FDA.
After joining multiple other…
After joining multiple other drugmakers on the U.S. investment bandwagon earlier this year, Gilead Sciences is providing further details on where it plans to channel its $32 billion pledge.
The drug manufacturer lobby’s…
The drug manufacturer lobby's seven-figure campaign, set to run through the end of the year, portrays fictional nonprofit hospital leaders celebrating profits derived from the program's discounts.
The move forms the next step in…
The move forms the next step in the company's long-held plan to exit manufacturing operations in India, with its Bangalore site expected to cease operations over the 2025-2026 Indian fiscal year.
The UK is losing business…
The UK is losing business opportunities in the life sciences sector because the government undervalues the economic and social benefits of investing in the manufacturing of innovative medicines, according to a report from the Cambridge